# NQO1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NQO1 is a homodimeric flavoenzyme crucial for the two-electron reduction of quinones, acting as a central antioxidant and xenobiotic detoxifier; its canonical function prevents the generation of reactive semiquinone radicals.
- The gene is transcriptionally regulated by the Keap1-Nrf2-ARE pathway, with inducible expression in response to oxidative stress and xenobiotics, and is subject to epigenetic silencing via promoter hypermethylation in certain cancers.
- Beyond its enzymatic role, NQO1 stabilizes tumor suppressors like p53 and p73α, modulates proteasomal degradation, and regulates transcription factors such as NF-κB and HIF-1α, highlighting its multifunctional nature.
- The common Pro187Ser polymorphism (rs1800566, C609T) results in a catalytically inactive and rapidly degraded NQO1 protein, significantly increasing susceptibility to various cancers (e.g., gastric, leukemia), cardiovascular diseases, and drug-induced toxicities.
- NQO1 is a key target for bioreductive anticancer prodrugs (e.g., β-lapachone) due to its frequent overexpression in tumors, and conversely, NQO1 inhibitors are explored for cancers where its activity promotes tumor progression or drug resistance.
- NQO1 plays a role in ferroptosis regulation by reducing lipid peroxides and interacts with the GPX4 pathway, and it is also expressed in the nervous system, where it confers neuroprotection against oxidative stress.

---

## Executive Summary & Key Metadata

NAD(P)H:quinone oxidoreductase 1 (NQO1), historically designated DT-diaphorase, is a homodimeric flavoenzyme that catalyzes the obligatory two-electron reduction of quinones, quinone imines, and nitroaromatic compounds, utilizing either NADH or NADPH as reducing cofactors. This activity positions NQO1 as a central node in cellular antioxidant defense, xenobiotic detoxification, and redox homeostasis. Beyond its canonical oxidoreductase function, NQO1 operates as a multifunctional protein that stabilizes tumor suppressor proteins (e.g., p53, p73α), modulates proteasomal degradation, and regulates transcription factors such as NF-κB and HIF-1α. The gene is inducibly expressed via the antioxidant response element (ARE)/Nrf2 pathway and is frequently overexpressed in a wide spectrum of human malignancies, making it an attractive target for bioreductive anticancer prodrugs and a prognostic biomarker. A common single nucleotide polymorphism (SNP), rs1800566 (C609T, Pro187Ser), results in a rapid loss of enzymatic activity and has been extensively studied for its association with susceptibility to various cancers, neurodegenerative disorders, cardiovascular diseases, and adverse drug reactions. This reference manual provides an exhaustive, publication-grade synthesis of the genomic architecture, structural biology, signaling networks, clinical genetics, pharmacogenomics, and bioinformatic resources pertaining to NQO1.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | NQO1 |
| **UniProt Accession** | P15559 |
| **Representative PDB ID** | 1D4A (human NQO1 in complex with duroquinone) |
| **Chromosomal Locus** | 16q22.1 |
| **Primary Molecular Function** | Two-electron reduction of quinones; antioxidant defense; protein stabilization |
| **Disease & Pathology Associations** | Cancer susceptibility (multiple types), neurodegenerative diseases, cardiovascular disease, ischemic stroke, diabetic nephropathy, drug-induced toxicity |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human NQO1 gene is localized to chromosome 16 at band q22.1, a region that is frequently subject to allelic loss and genomic alterations in various cancers [34]. The gene spans approximately 17 kilobases (kb) of genomic DNA and comprises six exons and five introns. The coding sequence is distributed across all six exons, with the translational start site located in exon 1 and the stop codon in exon 6. The genomic organization was first characterized in detail by Jaiswal in 1991, who demonstrated that the gene is inducible by dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) and other xenobiotics [16].

The promoter region of NQO1 lacks a canonical TATA box but contains a GC-rich region and multiple cis-acting regulatory elements. The most critical regulatory element is the antioxidant response element (ARE), also known as the electrophile response element (EpRE), located in the 5'-flanking region. This element mediates the transcriptional activation of NQO1 in response to a wide array of chemical inducers, including phenolic antioxidants, isothiocyanates (e.g., sulforaphane), and Michael acceptors [33, 94]. The ARE core sequence (5'-TGACnnnGC-3') is recognized by members of the basic leucine zipper (bZIP) transcription factor family, including Nrf2 (NFE2L2), Nrf1 (NFE2L1), and the AP-1 family proteins c-Fos and Fra1. Functional studies have established that Nrf1 and Nrf2 positively regulate ARE-mediated NQO1 expression, whereas c-Fos and Fra1 act as negative regulators [94]. Additionally, the transcription factor AP-2 has been shown to bind to specific promoter elements and modulate NQO1 gene expression [35].

### 1.2 Transcriptional Regulation and Epigenetic Control

The inducible expression of NQO1 is primarily governed by the Keap1-Nrf2-ARE signaling axis. Under basal conditions, Nrf2 is sequestered in the cytoplasm by its inhibitor Kelch-like ECH-associated protein 1 (KEAP1), which facilitates its ubiquitination and proteasomal degradation. Upon exposure to electrophiles or oxidative stress, critical cysteine residues in KEAP1 are modified, leading to Nrf2 stabilization and nuclear translocation. In the nucleus, Nrf2 heterodimerizes with small Maf proteins and binds to the ARE to drive the transcription of NQO1 and other phase II detoxifying enzymes [46, 54, 81]. This pathway is highly conserved and is a primary mechanism for cellular adaptation to oxidative insults.

Epigenetic mechanisms also contribute to the regulation of NQO1 expression. Hypermethylation of CpG islands within the NQO1 promoter has been documented in human hepatocellular carcinoma (HCC), leading to transcriptional silencing [26]. Similarly, DNA methylation of a non-CpG island promoter region was shown to repress NQO1 expression in rat arsenic-transformed lung epithelial cells, suggesting that aberrant methylation patterns may contribute to tumorigenesis by compromising antioxidant defenses [71]. In contrast, histone deacetylase (HDAC) inhibitors and other chromatin-modifying agents have been shown to induce NQO1 expression, indicating that the locus is subject to dynamic epigenetic regulation.

### 1.3 Alternative Splicing and Isoforms

While the primary transcript of NQO1 encodes a 274-amino acid protein, alternative splicing events have been described that generate multiple mRNA isoforms. The most well-characterized isoform, NQO1_v1, corresponds to the canonical full-length protein. A second isoform, NQO1_v2, results from alternative splicing in the 5' untranslated region (UTR) and does not alter the open reading frame. Other minor splice variants have been predicted in silico, but their protein products, if translated, would likely be non-functional due to premature stop codons or deletions of critical catalytic residues. The functional significance of these splice variants in human physiology and disease remains an area of active investigation. The NQO1 gene also shares significant sequence homology with a second gene, NQO2, which is located on chromosome 6p25 [34]. NQO2 encodes a distinct enzyme with different substrate specificity and cofactor preference, but it is often co-regulated with NQO1 in response to xenobiotics.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The human NQO1 protein is a 274-amino acid polypeptide with a molecular weight of approximately 30.8 kDa per monomer. The enzyme functions as a homodimer, with each monomer folding into a single globular domain that contains two distinct structural regions: an N-terminal cofactor-binding domain and a C-terminal catalytic domain. The N-terminal region (residues 1–50) is involved in dimerization and contributes to the binding of the FAD prosthetic group. The central region (residues 50–220) forms the core of the catalytic domain and contains the active site, which is deeply buried at the dimer interface. The C-terminal region (residues 220–274) contributes to substrate binding and stabilizes the overall fold.

### 2.2 Three-Dimensional Structure and Active Site Architecture

High-resolution crystal structures of human NQO1, including the representative PDB entry 1D4A, have revealed that the enzyme adopts a mixed α/β fold characteristic of the flavoprotein reductase family. Each monomer consists of a central parallel β-sheet flanked by α-helices, and the dimer interface is formed primarily by hydrophobic interactions and hydrogen bonds between the N-terminal regions of the two monomers. The FAD cofactor is non-covalently bound at the interface between the two domains, with the isoalloxazine ring positioned to facilitate hydride transfer from the nicotinamide ring of NAD(P)H to the substrate.

The active site is a narrow, solvent-accessible channel that accommodates a wide range of quinone substrates. The catalytic mechanism involves the transfer of a hydride ion from NAD(P)H to FAD, followed by the two-electron reduction of the quinone substrate to the corresponding hydroquinone. This mechanism bypasses the formation of reactive semiquinone intermediates, which is a key feature that distinguishes NQO1 from one-electron reductases such as cytochrome P450 reductase. The catalytic residues include Tyr128, which is critical for substrate binding and orientation, and His161, which participates in proton transfer. The Pro187 residue, which is the site of the common C609T polymorphism, is located in a loop near the FAD-binding site; substitution of this proline with serine (Pro187Ser) disrupts the local conformation and leads to rapid proteasomal degradation of the protein, resulting in a near-complete loss of enzymatic activity [64, 83].

### 2.3 Post-Translational Modifications and Protein Stability

NQO1 is subject to several post-translational modifications that modulate its stability and function. Acetylation of lysine residues has been reported to affect enzyme activity, while phosphorylation by protein kinase C (PKC) has been shown to influence its interaction with other proteins. The protein is also a substrate for the ubiquitin-proteasome system; however, NQO1 binding to p53 and other client proteins protects them from ubiquitin-independent degradation. The stability of NQO1 itself is regulated by chaperones such as Hsp70, which has been shown to stabilize NQO1 under conditions of heat shock, thereby increasing its activity and enhancing the cytotoxicity of NQO1-dependent bioreductive drugs like β-lapachone [25].

> **Interactive 3D Protein Visualizer: Load NQO1 (PDB: 1D4A)**
> [Interactive 3D Protein Visualizer: Load NQO1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P15559)
> This tool allows for the interactive exploration of the NQO1 homodimer, including the FAD cofactor, the active site cavity, and the location of the Pro187 residue. Users can rotate the model, highlight specific domains, and visualize the surface electrostatic potential.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Enzymatic Function: Quinone Detoxification

The primary enzymatic function of NQO1 is the two-electron reduction of quinones and their derivatives. This reaction is essential for the detoxification of a broad spectrum of environmental pollutants, dietary components, and endogenous metabolites, including menadione, benzo[a]pyrene-3,6-quinone, and estrogen quinones. By catalyzing the direct two-electron reduction, NQO1 prevents the formation of highly reactive semiquinone radicals that would otherwise undergo redox cycling with molecular oxygen, generating superoxide anions and other reactive oxygen species (ROS) [54, 64]. The importance of this function is underscored by studies in NQO1-null mice, which exhibit increased sensitivity to menadione-induced toxicity and develop myelogenous hyperplasia, a preleukemic condition [21, 22]. These findings establish NQO1 as a critical cytoprotective enzyme in the bone marrow and other tissues.

### 3.2 Non-Canonical Functions: Protein-Protein Interactions and Regulation of Transcription Factors

In addition to its enzymatic activity, NQO1 functions as a chaperone-like protein that regulates the stability and activity of several key signaling proteins. The most extensively studied interaction is with the tumor suppressor p53. NQO1 binds to p53 and protects it from ubiquitin-independent proteasomal degradation, thereby maintaining a functional p53 pool in response to DNA damage and oxidative stress. This interaction is particularly important in the context of cancer, where NQO1 overexpression may contribute to the maintenance of wild-type p53 activity. NQO1 also stabilizes p73α, another member of the p53 family, and modulates the activity of the transcription factor HIF-1α, which is central to the cellular response to hypoxia.

NQO1 has been shown to interact with the IκB kinase (IKK) complex and to suppress the activation of NF-κB. In prostate cancer cells, NQO1 inhibits the interaction between NF-κB and the transcriptional coactivator p300, thereby reducing the expression of pro-inflammatory and pro-tumorigenic genes [79]. This anti-inflammatory function is consistent with the observation that NQO1 expression correlates inversely with NF-κB activation in human breast cancer [97]. Furthermore, NQO1 has been implicated in the regulation of the AMPK/TSC2/mTOR signaling pathway, where its deficiency leads to enhanced autophagy in models of cisplatin-induced acute kidney injury [67]. These diverse protein-protein interactions highlight the multifunctional nature of NQO1 and its role as a central hub in cellular stress responses.

### 3.3 NQO1 in Redox Signaling and Ferroptosis

Recent studies have identified NQO1 as a key regulator of ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation. NQO1 has been shown to suppress ferroptosis by reducing lipid peroxides and by interacting with the glutathione peroxidase 4 (GPX4) pathway [45, 47]. For example, plumbagin, a natural naphthoquinone, targets NQO1/GPX4-mediated ferroptosis to suppress glioma growth [45]. Additionally, tanshinone, a compound derived from Salvia miltiorrhiza, functions as a coenzyme that confers a gain of function to NQO1, enabling it to detoxify lipid peroxyl radicals and inhibit ferroptosis both in vitro and in vivo [47]. These findings position NQO1 as a critical node in the regulation of ferroptotic cell death, with significant implications for cancer therapy and the treatment of degenerative diseases.

### 3.4 NQO1 in the Nervous System and Neurodegeneration

NQO1 is expressed in the central nervous system, where it plays a protective role against oxidative stress. The enzyme is upregulated in response to various insults, including excitotoxicity and mitochondrial dysfunction. In models of Parkinson's disease, induction of NQO1 by compounds such as KMS04014 has been shown to exert neuroprotective effects [77]. NQO1 also promotes neurite outgrowth by signaling through the Nrf2-NQO1 pathway in response to docosahexaenoic acid (DHA), an omega-3 fatty acid [51]. In the context of dopaminergic signaling, NQO1 has been shown to regulate the pharmaco-behavioral effects of d-amphetamine in the striatum, suggesting a role in modulating dopamine neurotransmission [62]. These observations are supported by genetic association studies linking NQO1 polymorphisms to neuropsychiatric conditions, including tardive dyskinesia and schizophrenia [14, 20, 28].

### 3.5 Protein-Protein Interaction Networks

NQO1 participates in a complex network of protein-protein interactions that extend beyond its role in xenobiotic metabolism. According to databases such as BioGRID and STRING, NQO1 interacts with a diverse array of partners, including:

- **Tumor suppressors**: TP53, TP73
- **Transcription factors**: NFE2L2 (Nrf2), HIF1A, NF-κB subunits (RELA)
- **Chaperones**: HSP70, HSP90
- **Proteasomal components**: PSMA1, PSMB5
- **Metabolic enzymes**: G6PD, TKT
- **Kinases**: AMPK, mTOR

These interactions are context-dependent and are influenced by the cellular redox state, the expression level of NQO1, and the presence of specific post-translational modifications. The dynamic nature of these interactions underscores the role of NQO1 as a stress-responsive hub that coordinates multiple cellular processes.

```mermaid
sequenceDiagram
    participant Electrophile
    participant Keap1
    participant Nrf2
    participant Nucleus
    participant ARE
    participant NQO1
    participant Substrate

    Electrophile->>Keap1: Modifies Cys residues
    Keap1-->>Nrf2: Releases Nrf2
    Nrf2->>Nucleus: Translocates
    Nrf2->>ARE: Binds (with Maf)
    ARE->>NQO1: Activates transcription
    NQO1->>Substrate: Reduces quinone (2e-)
    Note over NQO1,Substrate: Produces hydroquinone, prevents ROS
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The NQO1*2 Polymorphism (rs1800566, C609T, Pro187Ser)

The most extensively studied genetic variant in the NQO1 gene is a C to T transition at nucleotide position 609 in exon 6, which results in a proline to serine substitution at codon 187 (Pro187Ser). This variant, designated NQO1*2, is a loss-of-function polymorphism. The mutant protein is catalytically inactive and is rapidly degraded by the ubiquitin-proteasome system, resulting in a near-complete absence of NQO1 enzymatic activity in individuals homozygous for the T allele (NQO1*2/*2). Heterozygous individuals (NQO1*1/*2) exhibit intermediate enzyme activity. The allele frequency of the NQO1*2 variant varies significantly across populations, with a prevalence of approximately 20% in Asian populations and 4-5% in individuals of European descent [83].

### 4.2 NQO1 Polymorphisms and Cancer Susceptibility

The NQO1*2 polymorphism has been the subject of numerous case-control studies and meta-analyses investigating its association with cancer risk. The results have been highly variable, with some studies reporting significant associations and others finding no effect. A comprehensive meta-analysis by Lajin and Alachkar concluded that the NQO1 C609T polymorphism is associated with a modestly increased risk of overall cancer, particularly for certain tumor types [83]. Specific associations have been reported for:

- **Digestive tract cancers**: Multiple meta-analyses have demonstrated an increased risk of gastric cancer and colorectal cancer associated with the NQO1*2 allele, particularly in Asian populations [4, 8, 13, 55, 85, 96]. The association with esophageal cancer has also been explored, with conflicting results [36, 59].
- **Leukemia**: The NQO1*2 variant has been associated with an increased risk of both adult and childhood leukemia, particularly therapy-related acute myeloid leukemia (t-AML) and acute lymphoblastic leukemia (ALL) [17, 29, 32, 37, 69, 93, 95]. The risk appears to be modulated by interactions with other genetic variants, such as CYP1A1 polymorphisms [32, 69].
- **Lung cancer**: A case-control study and meta-analysis by Guo et al. found no significant association between the NQO1 C609T polymorphism and lung cancer risk [12]. However, other studies have suggested that the variant may modify the risk associated with tobacco smoking.
- **Hepatocellular carcinoma**: Studies have reported both positive and null associations between the NQO1*2 allele and HCC risk [86, 91].
- **Head and neck cancer**: A study by Cho et al. investigated the association of GSTP1 and NQO1 polymorphisms with head and neck squamous cell carcinoma risk [82].
- **Bladder cancer**: The NQO1*2 variant has been shown to interact with smoking to increase bladder cancer risk [87].

The discrepancies in these findings may be attributed to differences in population genetic backgrounds, sample sizes, and the modifying effects of environmental exposures. Nevertheless, the NQO1*2 polymorphism is widely regarded as a low-penetrance susceptibility allele for several types of cancer.

### 4.3 NQO1 Polymorphisms and Non-Malignant Diseases

Beyond cancer, the NQO1*2 polymorphism has been investigated for its role in a wide range of diseases:

- **Cardiovascular disease**: The NQO1 C609T polymorphism has been associated with an increased risk of ischemic stroke in the Chinese Han population [1]. A gender-dependent association with coronary artery disease has also been reported [80]. Furthermore, genetic variations in NQO1, along with NRF2, HMOX1, and MT, have been linked to the severity of coronary artery disease [53].
- **Chronic kidney disease**: NQO1 expression is enhanced in mononuclear cells from patients with chronic kidney disease, suggesting a compensatory response to increased oxidative stress [2]. The NQO1*2 polymorphism has been associated with an increased risk of diabetic nephropathy [73].
- **Neuropsychiatric disorders**: The NQO1*2 variant has been studied for its association with schizophrenia, tardive dyskinesia, and mood disorders. While some studies have reported an association with tardive dyskinesia [14, 20], others have found no association with schizophrenia or mood disorders [28, 39]. A study by Agúndez et al. found no association between the NQO1 rs1800566 variant and multiple sclerosis risk [9], although a combined analysis of GSTP1 and NQO1 polymorphisms suggested a potential role in MS susceptibility [78].
- **Asthma**: The NQO1*2 polymorphism has been associated with childhood asthma and has been shown to predict the intensity of empirical treatment [5, 15].
- **Drug-induced toxicity**: The NQO1*2 variant has been implicated in the risk of anthracycline-related congestive heart failure in childhood cancer survivors [11] and anti-tuberculosis drug-induced liver injury [58]. It also influences warfarin dose requirements in patients with atrial fibrillation [7].

### 4.4 Other NQO1 Variants

While the C609T polymorphism is the most well-studied, other variants in the NQO1 gene have been identified. These include a C465T polymorphism (rs4986998) that results in a synonymous change and a G174A polymorphism (rs1131341) that leads to a Val45Ile substitution. The functional significance of these variants is less clear, but they may contribute to inter-individual variability in NQO1 activity.

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Rev and NQO1

NQO1 has been identified as a host factor that modulates the replication of human immunodeficiency virus type 1 (HIV-1). A study by Lata et al. demonstrated that the HIV-1 regulatory protein Rev induces the expression of NQO1, which in turn mediates the degradation of the viral protein Tat [76]. Tat is essential for viral transcription, and its degradation by the NQO1-dependent pathway results in the inhibition of viral replication. This study revealed a novel antiviral mechanism in which the host cell utilizes NQO1 to counteract HIV-1 infection. The interaction between Rev and NQO1 highlights the complex interplay between viral pathogens and the host antioxidant defense system.

### 5.2 NQO1 and Other Pathogens

The role of NQO1 in host-pathogen interactions extends beyond HIV-1. As a key enzyme in the detoxification of xenobiotics, NQO1 may influence the metabolism of drugs used to treat various infections. For example, the NQO1*2 polymorphism has been associated with an increased risk of anti-tuberculosis drug-induced liver injury, suggesting that NQO1 plays a role in the metabolism and detoxification of isoniazid and other anti-TB drugs [58]. Furthermore, NQO1 expression is induced by various bacterial and viral components that activate the Nrf2 pathway, suggesting that it may be part of the host's innate immune response to infection.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NQO1 as a Target for Bioreductive Anticancer Drugs

The high expression of NQO1 in many solid tumors, including non-small cell lung cancer (NSCLC), breast cancer, and hepatocellular carcinoma, has made it an attractive target for bioreductive anticancer therapy [18, 24, 44, 66]. Bioreductive drugs are prodrugs that are activated by NQO1 to generate cytotoxic species selectively within tumor cells. The most well-known NQO1 substrate is β-lapachone, a naturally occurring naphthoquinone that is currently in clinical trials. β-lapachone is reduced by NQO1 to a hydroquinone that undergoes rapid auto-oxidation, generating a futile redox cycle that produces high levels of ROS, leading to DNA damage and cell death. The cytotoxicity of β-lapachone is directly proportional to NQO1 expression levels, and heat shock has been shown to increase NQO1 activity and enhance β-lapachone cytotoxicity [25].

Other NQO1-directed bioreductive agents include mitomycin C, EO9 (apaziquone), and RH1. The efficacy of these agents is dependent on the NQO1 status of the tumor, and the NQO1*2 polymorphism has been shown to predict response to these drugs. For example, an isogenic human colon tumor model for NQO1 gene expression was established to investigate the role of DT-diaphorase in bioreductive drug activation, demonstrating that NQO1-expressing cells are significantly more sensitive to these agents [23].

### 6.2 NQO1 Inhibitors

In contrast to the therapeutic strategy of exploiting NQO1 for drug activation, NQO1 inhibitors are being developed for the treatment of cancers where NQO1 activity promotes tumor progression or drug resistance. NQO1 has been shown to mediate resistance to lenvatinib in hepatocellular carcinoma by regulating ROS-induced apoptosis [42]. Therefore, inhibiting NQO1 may resensitize tumors to chemotherapy. Several small-molecule NQO1 inhibitors have been identified, including:

- **Dicoumarol**: A competitive inhibitor of NQO1 that has been used experimentally to sensitize cancer cells to various chemotherapeutic agents.
- **ES936**: A potent, mechanism-based inhibitor of NQO1 that has shown antitumor activity in preclinical models.
- **Dual inhibitors**: A dual inhibitor of NQO1 and GSTP1 has been discovered for treating glioblastoma [50]. This compound targets both enzymes to disrupt the antioxidant defense of tumor cells and enhance the efficacy of radiotherapy and chemotherapy.
- **Hybrid compounds**: Hybrids of 1,4-quinone with quinoline or betulin derivatives have been synthesized and evaluated for their anticancer activity and ability to interact with NQO1 [49, 57].

### 6.3 NQO1 in Drug Resistance and Pharmacogenomics

NQO1 expression and genetic polymorphisms have significant implications for the response to various anticancer drugs. A high-throughput screening study using the 1000 Genomes cell lines identified an association between the NQO1 gene and the response to multiple anticancer drugs, including doxorubicin and cyclophosphamide [3]. Specifically, the NQO1*2 allele has been associated with a poor response to adjuvant doxorubicin and cyclophosphamide therapy in breast cancer patients [98]. Similarly, NQO1 expression has been linked to resistance to sorafenib, lenvatinib, and regorafenib in hepatocellular carcinoma [42, 88]. These findings highlight the importance of NQO1 genotyping and expression analysis in the context of personalized cancer therapy.

### 6.4 NQO1 and Non-Cancer Therapeutics

The role of NQO1 extends beyond oncology. NQO1 is a target for the development of neuroprotective agents for the treatment of Parkinson's disease and other neurodegenerative disorders. Compounds that induce NQO1 expression, such as sulforaphane and KMS04014, have shown neuroprotective effects in preclinical models [74, 77]. NQO1 also plays a role in the response to environmental toxins, and its activity can be modulated by dietary compounds such as curcumin, quercetin, and caffeic acid phenethyl ester [27, 30, 56]. Furthermore, NQO1 is involved in the metabolism of warfarin, and its genetic variants influence warfarin dose requirements [7].

### 6.5 Novel Therapeutic Approaches

Recent advances have led to the development of novel NQO1-based therapeutic strategies. One such approach involves the use of NQO1-activatable circular antisense oligonucleotides (cASOs) for tumor-cell-specific gene silencing [10]. These cASOs are designed to be activated by NQO1, which is highly expressed in tumor cells, leading to the selective silencing of target genes such as survivin. This approach offers a promising strategy for targeted cancer therapy with reduced off-target effects.

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of key bioinformatic resources and database accessions for the NQO1 gene and protein.

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 1728 | Gene-specific information, genomic context, and links to related data. |
| **Ensembl** | ENSG00000181019 | Genome annotation, transcripts, and variation data. |
| **UniProt** | P15559 | Protein sequence, function, post-translational modifications, and structure. |
| **RCSB PDB** | 1D4A, 2F1O, 4CET | Experimentally determined 3D structures of human NQO1. |
| **HGNC** | 2874 | Gene symbol, name, and approved nomenclature. |
| **OMIM** | 125860 | Mendelian inheritance, phenotype, and clinical descriptions. |
| **ClinVar** | rs1800566 | Clinical significance of genetic variants. |
| **dbSNP** | rs1800566, rs1131341, rs4986998 | Single nucleotide polymorphisms and other small variants. |
| **Gene Ontology (GO)** | GO:0004128 (oxidoreductase activity), GO:0006749 (quinone metabolic process), GO:0005737 (cytoplasm) | Functional annotation of the gene product. |
| **STRING** | 9606.ENSP00000356150 | Protein-protein interaction networks. |
| **BioGRID** | 112358 | Physical and genetic interactions. |
| **PharmGKB** | PA321 | Pharmacogenomic knowledge and dosing guidelines. |
| **GTEx Portal** | NQO1 | Tissue-specific gene expression data. |
| **Human Protein Atlas** | ENSG00000181019 | Protein expression and localization in human tissues and cells. |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Yan, L., Xu, D., Xiao, Y.-F., Dai, M., Wang, T., Zhuang, X., & Wu, K. (2022). Genetic Polymorphism of NQO1 Gene is Associated with Susceptibility of Ischemic Stroke in Chinese Han Nationality. *Neuropsychiatric Disease and Treatment*. https://www.semanticscholar.org/paper/7c244993a8f8ba259f01536bc561e809439d78a2
2. Shen, J., Rasmussen, M., Dong, Q., Tepel, M., & Scholze, A. (2017). Expression of the NRF2 Target Gene NQO1 Is Enhanced in Mononuclear Cells in Human Chronic Kidney Disease. *Oxidative Medicine and Cellular Longevity*. https://www.semanticscholar.org/paper/3c87b483c9c9335d97475b085bf151967538e5db
3. Akhtari, F., Green, A. J., Small, G., Havener, T. M., House, J., Roell, K., Reif, D. M., McLeod, H., Wiltshire, T., & Motsinger-Reif, A. (2021). High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. *PLoS Genetics*. https://www.semanticscholar.org/paper/8c42093c226de5b28ede0973b30a359673935384
4. Yadav, U., Kumar, P., & Rai, V. (2018). NQO1 Gene C609T Polymorphism (dbSNP: rs1800566) and Digestive Tract Cancer Risk: A Meta-Analysis. *Nutrition and Cancer*. https://www.semanticscholar.org/paper/bd8864ebf6d5de60201ff8a726d68e1b9e4a8e60
5. Guo, S., Liu, F., Ren, C., Xing, C., & Wang, Y. (2019). Correlations of LTα and NQO1 gene polymorphisms with childhood asthma. *European Review for Medical and Pharmacological Sciences*. https://www.semanticscholar.org/paper/7d10831bc5fc986e8304ca925a6b7dd7dc82e33f
6. Ahmadi, N., Mandegary, A., Jamshidzadeh, A., Mohammadi-Sardoo, M., Mohammadi-Sardo, M., Salari, E., & Pourgholi, L. (2018). Hematological Abnormality, Oxidative Stress, and Genotoxicity Induction in the Greenhouse Pesticide Sprayers; Investigating the Role of NQO1 Gene Polymorphism. *Toxics*. https://www.semanticscholar.org/paper/10657b7ee2a7224166d5ca3dab0fea1b6110dde5
7. Li, J., Yang, W., Xie, Z., Yu, K., Chen, Y., & Cui, K. (2018). Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. *BMC Cardiovascular Disorders*. https://www.semanticscholar.org/paper/5bf67f5c1cc0ba5dcec746691bf1f85f9f3cf7e8
8. Hu, W.-G., Hu, J.-J., Cai, W., Zheng, M.-H., Zang, L., Wang, Z., & Zhu, Z.-G. (2014). The NAD(P)H: quinine oxidoreductase 1 (NQO1) gene 609 C>T polymorphism is associated with gastric cancer risk: evidence from a case-control study and a meta-analysis. *Asian Pacific Journal of Cancer Prevention*. https://www.semanticscholar.org/paper/0d6e6277b2271072e081461b6b3a1b8dbf389483
9. Agúndez, J., García-Martín, E., Martínez, C., Benito-León, J., Millán-Pascual, J., Calleja, P., Díaz-Sánchez, M., Pisa, D., Turpín-Fenoll, L., Alonso-Navarro, H., Ayuso-Peralta, L., Torrecillas, D., Plaza-Nieto, J. F., & Jiménez-Jiménez, F. (2014). NQO1 gene rs1800566 variant is not associated with risk for multiple sclerosis. *BMC Neurology*. https://www.semanticscholar.org/paper/62b2978c43fb18e690289e03aab0034e1c7b63e6
10. Zhao, X., Xu, J., Liang, X., Wang, Z., Zhu, Y., Guo, D., Wang, J., Amu, G., Wang, Q., Yang, Z., & Tang, X. (2025). NQO1-Activatable Circular Antisense Oligonucleotides for Tumor-Cell-Specific Survivin Gene Silencing and Antitumor Therapy. *Journal of Medicinal Chemistry*. https://www.semanticscholar.org/paper/9bb9fff5777737d26a46726083c878e7f06cdbbb
11. Blanco, J., Leisenring, W., González-Covarrubias, V., Kawashima, T., Davies, S., Relling, M., Robison, L., Sklar, C., Stovall, M., & Bhatia, S. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. *Cancer*. https://www.semanticscholar.org/paper/ed151d80bcf3c179312a7dbbc4e8db3d050b3517
12. Guo, S.-J., Gao, M.,